TRACON reports Q1 net loss $3.2M, cash $8.0M; ENVASARC final data due Q3 2024

Tracon Pharmaceuticals, Inc.

2024-Q1 EPS reported -$1.33 revenue$100,000

Net loss for Q1 2024 was $3.2M, down from $8.5M in Q1 2023.
Cash, cash equivalents and restricted cash were $8.0M at March 31, 2024, expected to fund operations late into Q3 2024.
ENVASARC Phase 2 pivotal trial fully enrolled; final response assessment data expected in Q3 2024.
Interim data: ORR 11% by investigator and 5.5% by BICR; median duration of response >6 months.
Nasdaq listing extension granted through June 3, 2024, subject to reverse stock split and S-1 filing (both completed in April 2024).

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Tracon Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: net income Net loss for the first quarter of 2024 was $3.2 million.

Period: the first quarter ended March 31, 2024
Net income: Net loss for the first quarter of 2024 was $3.2 million
Result: reported results

Exact text from the filing

TRACON Pharmaceuticals, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0000950170-24-059509

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.